A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients
NCT05281926
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
Poly ICLC
Sponsor
National Taiwan University Hospital